MIRA Pharmaceuticals Advances MIRA-55 Toward Q1 2027 IND
MIAMI, September 1, 2026 MIRA Pharmaceuticals, Inc. has reported positive results from completed 7-day dose-range finding toxicology and toxicokinetic...
Prescription, Generic, and Over-The-Counter: Drugs & Products.
AstraZeneca Tagrisso Combo Improves Lung Cancer PFS
Cambridge, UK, September 1, 2026 AstraZeneca has announced positive high-level results from the Phase III SANOVO trial, showing that...
Kyowa Kirin Reaches U.S. Agreement to Lower Medicine Costs
TOKYO, Japan and PRINCETON, New Jersey, Aug. 31/Sept. 1, 2026 Kyowa Kirin Co., Ltd. announced a voluntary agreement with...
Astellas Reaches U.S. Agreement on Medicine Affordability
TOKYO, Japan, Aug. 31, 2026 Astellas Pharma Inc. has entered into a voluntary agreement with the U.S. government designed...
AstraZeneca, Daiichi Sankyo Win EU Approval for Enhertu
CAMBRIDGE, UK, Sept. 1, 2026 AstraZeneca and Daiichi Sankyo announced that the European Commission has approved Enhertu (trastuzumab deruxtecan)...
UCB Agreement Targets Medicine Costs and U.S. Manufacturing
BRUSSELS, Belgium and ATLANTA, Georgia, Aug. 31, 2026 UCB has reached an agreement with the U.S. government aimed at...
Teva Advances U.S. Deal on Affordable Medicines and Supply
PARSIPPANY, N.J., and TEL AVIV, Israel, August 31, 2026 Teva Pharmaceuticals announced a shared commitment with the Trump Administration...
BeOne Medicines Expands U.S. Cancer Access and Manufacturing
SAN CARLOS, Calif., August 31, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company,...
Amarin Highlights New REDUCE-IT Data at ESC 2026
DUBLIN and BRIDGEWATER, N.J., August 31, 2026 Amarin Corporation plc highlighted new findings from multiple REDUCE-IT® analyses presented at...
Karmanos Offers FDA-Approved Daraxonrasib for Cancer
Detroit, Michigan, August 31, 2026 The Barbara Ann Karmanos Cancer Institute announced that it is now offering FDA-approved daraxonrasib...